Inhibrx Biosciences (INBX) Projected to Announce Quarterly Earnings on Friday

Inhibrx Biosciences (NASDAQ:INBX) is expected to announce its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect the company to announce earnings of ($2.45) per share and revenue of $1.90 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX) last posted its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.28) by ($0.06). On average, analysts expect Inhibrx Biosciences to post ($9.91) EPS for the current fiscal year and ($9.34) EPS for the next fiscal year.

Inhibrx Biosciences Stock Performance

NASDAQ:INBX opened at $90.61 on Wednesday. Inhibrx Biosciences has a 52 week low of $57.30 and a 52 week high of $155.29. The stock’s fifty day moving average is $97.47 and its two-hundred day moving average is $91.94.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on INBX. Citigroup reiterated a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. HC Wainwright initiated coverage on shares of Inhibrx Biosciences in a report on Monday, August 24th. They issued a “buy” rating and a $245.00 price objective on the stock. Wall Street Zen cut shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $197.50.

Insider Buying and Selling at Inhibrx Biosciences

In other news, Director Jon Kayyem bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 23rd. The shares were bought at an average price of $100.00 per share, with a total value of $500,000.00. Following the completion of the transaction, the director directly owned 434,360 shares in the company, valued at $43,436,000. This trade represents a 1.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark Lappe purchased 10,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were purchased at an average price of $84.56 per share, for a total transaction of $848,982.40. Following the completion of the purchase, the chief executive officer directly owned 745,588 shares of the company’s stock, valued at $63,046,921.28. This represents a 1.36% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. 18.26% of the stock is owned by corporate insiders.

About Inhibrx Biosciences

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.